TAK-901
- Generic Name
- TAK-901
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32N4O3S
- CAS Number
- 934541-31-8
- Unique Ingredient Identifier
- DM9UIR23R7
- Background
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00935844
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00807677
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath